Lilly raises 2021 revenue guidance to $28.0B-$28.3B; 2022 EPS seen at $8.00-$8.15

ELI LILLY & Co

2021 revenue guidance raised to $28.0B-$28.3B (from $27.2B-$27.6B); non-GAAP EPS raised to $8.15-$8.20.
2022 revenue guidance $27.8B-$28.3B; reported EPS $8.00-$8.15; non-GAAP EPS $8.50-$8.65.
Initiated rolling FDA submission for pirtobrutinib in MCL; completion in 2022, regulatory action early 2023.
Plans new phase 3 studies for tirzepatide in obesity outcomes, sleep apnea, and kidney disease; donanemab biomarker data disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.